Status:
COMPLETED
Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Epstein-Barr Viraemia
Hematologic Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Scientific context Epstein-Barr virus has a causal role in the pathogenesis of multiple distinct lymphomas. Post-transplant lymphoproliferative diseases (PTLD) are the most frequent EBV-induced proli...
Detailed Description
Study duration : Total study duration: 37 months Duration of recruitment: 24 months Duration of participation for each patient: 13 months Inclusion criteria: Retrospective study: Patient who underw...
Eligibility Criteria
Inclusion
- Retrospective study:
- Patient who underwent HSCT, in Saint-Antoine hospital,
- between 2010-2015,
- treated by rituximab for high level EBV-DNAemia (above 3.3 log copies/mL).
- Prospective study:
- Patients who underwent HSCT, in Saint-Antoine hospital and la Pitié-Salpêtrière,
- in 2017-2018,
- treated by rituximab for high level EBV-DNAemia (above 10 000c/mL),
- And/or having post-transplant lymphoproliferative diseases(PTLD)
Exclusion
- Refusal to sign the informed consent
- Patient non-beneficiary of the Social Security system
Key Trial Info
Start Date :
December 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 5 2021
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT03343834
Start Date
December 21 2017
End Date
August 5 2021
Last Update
October 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'hématologie Clinique
Paris, France, 75012